|
|
|
| Strain Number: | 01XB4 | ||
| Common Strain Name: | TetO-HRAS | ||
| Strain Nomenclature: | FVB-Tg(tetO-HRAS)65Lc | ||
| Release Category (Required for MTA form): B,D | |||
| Animal Health Report in PDF Format | |||
| Strain Description: | This strain carries an activated HRAS human gene (G12V) under the control of a minimal promoter containing multimerized tet-operons (TetO). TetO will drive expression of the HRAS transgene in the presence of a tetracycline transcriptional activator(tTA), or a tetracycline reverse transcriptional activator (rtTA), in the absence or presence of doxycycline (Dox), respectively. In normal use this strain would be mated with a transgenic strain carrying tTA or rtTA under the control of a tissue specific promoter/enhancer. | ||
| Mutation Information | |||
| Mutation Type: | Transgenic | ||
| Gene Name: | |||
| Gene Symbol: | |||
| Transgene Name: | RAS oncogene | ||
| Transgene Symbol: | HRAS | ||
| Promoter Name: | Tet Operon | ||
| Promoter Symbol: | TetO | ||
| Current Genetic Background: | FVB/N | ||
| Approx. Generation: | 11 | ||
| Organ Site : | All | ||
| Cryopreservation Mating Scheme: | FVB/N females x hemizygous males | ||
| Genotyping Information: | Protocol 1: Allele: Tg(TetO-HRAS)65Lc | ||
| Donating Investigator: | Dr. Lynda Chin | ||
| Key Reference: | Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q et.al. 1999. Essential role for oncogenic Ras in Tumour maintenance. Nature 400:468-72. PMID: 10440378 [PubMED Abstract] | ||
 |
 |
 |